Lonza Group

What they make

6 inputs Lonza Group supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Where they make it

5 facilities

Intelligence

What's known

Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.

• Did you know2024

  Lonza is one of the most important companies in medicine that almost no patient has heard of, because it doesn't sell drugs under its own name — it makes them for others. Lonza is among the world's largest CDMOs (contract development and manufacturing organizations): pharmaceutical and biotech companies hand it their molecules and Lonza manufactures them at scale. Most famously, Lonza produces the mRNA drug substance for Moderna's COVID-19 vaccine. And through its Capsugel business it is also a dominant maker of the world's empty pharmaceutical capsules — the gelatin and HPMC shells that physically hold powdered medicines and supplements. So a single Swiss company sits behind both a landmark vaccine and the literal casing of countless pills people swallow every day. The "brand" on a medicine is a pharma company's; the actual molecule, and often the capsule around it, may well be Lonza's. It is the hidden contract factory of the drug industry — a chokepoint of manufacturing capacity rather than of any one product.

  Lonza Group AG ↗

• Chokepoint2024

  The modern pharma industry has increasingly stopped building its own factories and instead rents capacity from a handful of contract manufacturers — Lonza, Catalent, Thermo Fisher (Patheon), Samsung Biologics, WuXi and a few others — which makes that outsourced capacity a strategic chokepoint. Biologics, mRNA, antibody-drug conjugates and cell-and-gene therapies all require specialized, scarce, slow-to-build manufacturing lines, so when demand spikes (as it did for COVID vaccines) the binding constraint is often not the science but whether a CDMO has open suite time. Lonza sits at the center of this. The same logic extends to the unglamorous capsule: empty pharmaceutical capsules are a near-duopoly (Lonza/Capsugel and India's ACG), and essentially every powder-filled oral drug and supplement needs one. So both the cutting-edge biologic and the humble capsule that delivers a pill depend on very few suppliers — and geopolitics is now intruding too, as proposed U.S. restrictions on Chinese CDMOs (the BIOSECURE Act targeting WuXi) threaten to reshuffle who the West can use, raising Lonza's strategic importance further. [verify: CDMO chokepoint (Lonza et al) + Capsugel/ACG capsule duopoly + BIOSECURE/WuXi established]

  Lonza Group AG ↗

• Origin2023

  Lonza was founded in 1897 in Gampel, Valais, Switzerland — taking its name from the Lonza River whose hydroelectric power was used to run electrolytic nitrogen fixation plants for fertilizer production. Lonza used cheap Swiss hydropower to make carbide and acetylene at a time when cheap energy was the primary cost driver in chemical manufacturing. The chemical heritage expanded to vitamins, enzymes, and specialty chemicals over the 20th century. In 1999, Lonza acquired Microbiological Associates (a US biologic testing company) and began the pivot to pharmaceutical manufacturing. The transformative shift was acquiring Celltech Biologics in 2004 — UK bioreactor technology that became the foundation of Lonza's biologic CDMO business. By 2020, when Moderna had no manufacturing capacity for their mRNA vaccine, Lonza's Visp, Switzerland facility (built on the same site as their 1897 hydroelectric chemical factory) manufactured the mRNA drug substance. A hydroelectric nitrogen fixation company became the facility that manufactured the active ingredient of the first mRNA vaccine in human history.

  Lonza Group AG ↗

• Concentration2023

  Lonza Group's $5.5 billion acquisition of Capsugel in 2017 — combining Lonza (world's largest pharmaceutical contract development and manufacturing organization / CDMO) with Capsugel (world's largest empty hard-shell capsule manufacturer, formerly Pfizer's capsule division, then KKR PE portfolio) — created an unusual situation where the same company is simultaneously: (1) a major CDMO that develops and manufactures drug formulations for pharmaceutical clients (including those clients' capsule-filled products), and (2) the primary supplier of the empty capsule shells those drugs are put in. A pharmaceutical company that hires Lonza to fill and manufacture its drug capsule product is simultaneously buying the capsule shells from Lonza's Capsugel division. This creates a unique relationship where Lonza has visibility into both the drug formulation details (CDMO client) and the capsule supply chain (Capsugel client). Lonza's Capsugel concentration also means that a fire, force majeure, or regulatory shutdown at any major Capsugel manufacturing site would affect a significant fraction of global pharmaceutical finished dose production — capsule shells have essentially no inventory buffer (produced just-in-time for drug filling operations).

  Lonza Group AG ↗